ReviewRheumatology international2012
The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review.
Review in Rheumatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Rosuvastatin alters the genetic composition of the human gut microbiome.Scientific reports · 2020Trial
- Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease.AIDS (London, England) · 2017Trial
- Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults.Antiviral therapy · 2017Trial
- The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases.The Journal of rheumatology · 2018Article
- Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.Archives of medical science : AMS · 2015Article
- Herpes zoster is associated with prior statin use: a population-based case-control study.PloS one · 2014Article
- The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in renal disease.International journal of nephrology and renovascular disease · 2014Review
- Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.American journal of respiratory cell and molecular biology · 2013Article
- Beyond lipid lowering: pleiotropic effects of statins in heart failure.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2013Article
- Revisiting secondary amyloidosis for an inadequately investigated feature: dyslipidemia.Rheumatology international · 2013Article
- Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials.Current pharmaceutical design · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hydroxy-methyl-glutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment for hyperlipidemia. They have also demonstrated a benefit in a variety of other disease processes, including a wide range of rheumatologic disorders. These secondary actions are known as pleiotropic effects. Our paper serves as a focused and updated discussion on the pleiotropic effects of statins in rheumatologic disorders and emphasizes the importance of randomized, placebo-controlled trials to further elucidate this interesting phenomenon.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.